Albany, NY -- (SBWIRE) -- 10/07/2014 -- Organ transplant immunosuppressants are a class of drugs administered to lower the chances of organ rejection after a transplant and are also called as anti-rejection drugs. When a person gets an organ transplant such as kidney, liver or heart, the body identifies transplant as a foreign tissue and attacks it causing severe rejection. These immunosuppressant drugs weaken the immune system thereby decreasing the body’s reaction to transplant. Almost every person undergoing a solid organ transplant requires to take immunosuppressant drugs. Therefore the global market for these drugs is sharply rising with increase in the number of organ transplants across the globe.

Browse Full Report with TOC @ http://www.transparencymarketresearch.com/organ-transplant-immunosuppressant-drugs.html

The global market for organ transplant immunosuppressant drugs is segmented on the basis of drug classes into calcineurin inhibitors (cyclosporine, tacrolimus); mTOR inhibitors (sirolimus, everolimus); purine synthesis (IMDH) inhibitors (mycophenolatemofetil, enteric-coated mycophenolic acid (EC-MFS), mizoribine (MZR)); pyrimidine synthesis (DHODH) inhibitors (leflunomide, azathioprine); depleting antibodies (horse or rabbit antithymocyte globulin, muromonab-CD3, alemtuzumab, rituximab), non-depleting antibodies and fusion proteins (daclizumab, basiliximab, belatacept), protease inhibitor (bortezomib); and C5 inhibitor (eculizumab).

The global market for these drugs can also segmented into five major transplant areasof theheart, kidney, lung, liver and pancreas in addition to segmentation by geographies namely, North America, Europe, Asia - Pacific and Rest of the World.Canadian Institute for Health Information identified a 5% increase over 2011 in organ transplants in 2012 with 2,225 procedures performed, yet as deceased organ donors are still very less over the world, a consistent rise is hard to predict in the near future. Deceased donors can provide up to 8 organs whereas live donors can provide only a single kidney in most cases which has increased organ transplant waiting time considerable over the years.According to the Organ Procurement and Transplantation Network (OPTN), more than 1 million patients are on waiting list for organ transplant.

As the number of organ donors is increasing, an increase in transplant procedures is bound to happen which will expand the global market for organ transplant immunosuppressant drugs. However, due to costlier procedure the market shift will occur in Asia-Pacific countries where medical tourism is being promoted. The major restraint for the market is a significant risk of infection after administering these drugs.While preventing rejection of transplanted organ by immunosuppression, these drugs make patient vulnerable to variety of infections. Therefore, saferimmunosuppressant drugs with better balance between preventing rejection and infection susceptibility shall be in demand in the near future.

Some of the major players in the global organ transplant immunosuppressant drugs market are AstellasPharma, Accord Healthcare Ltd., Inc., Novartis AG, Genzyme Corporation, Watson Pharmaceuticals,Inc.,Mylan Laboratories, Inc., GlaxoSmithKline plc, and Hoffman La Roche.

This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include

- North America
- Asia Pacific
- Europe
- Rest of the World

This report provides comprehensive analysis of

- Market growth drivers
- Factors limiting market growth
- Current market trends
- Market structure
- Market projections for upcoming years

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

Read More Reports on Pharmaceutical Market: http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html

About Transparency Market Research
Transparency Market Research (TMR) is a market intelligence company providing global business research reports and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers.

TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources along with various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information which is indispensable for businesses to sustain their competitive edge.

Enquiry before Buying @ http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1967

Latest Upcoming Reports: http://www.transparencymarketresearch.com/upcoming.htm

Contact Us

Sheela AK
Corporate Office:
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States.

Tel: +1-518-618-1030
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

Browse Market Research Blogs:
http://www.tmrblog.com/
http://pharmaceuticalmarket.wordpress.com/